This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Diabetes Landscape: Market, Technology And Intellectual Property

Prospects for new market entrants

Although the diabetes devices market comprises close to 100 companies, it is dominated by just six major manufacturers: Roche, Johnson & Johnson (J&J), Bayer, Medtronic, Abbott and Becton Dickinson. Given the importance of SMBG in the overall diabetes device market, it follows that most of these companies owe their strong market position to offerings in this area, where brand recognition and a strong sales and marketing presence are vital. Although the significant market positions of the top six companies imply there is little room for smaller companies, there do remain goodopportunities for companies with unique products or devices that compete in yet-to-be established markets.

For example, Insulet has grown its sales from just US$4 million in 2006 to nearly US$120 million in 2011 as a result of offering a unique insulin pump with significant benefits over those offered by the established market leaders. Its OmniPod was the world's first tubing-free insulin pump, meaning it is smaller than many other devices; can be worn more discreetly; eliminates interruptions in insulin delivery due totubing kinks, leaks or disconnections; and, enables patients to move, dress, sleep and exercise more easily. A forensic investigation of 5,900 patents in the diabetes device area has been distilled to provide a detailed assessment of who holds key technology patents worldwide.

This volume provides an in-depth analysis of the technologies and IP associated with diabetes devices, including:

Diabetes Monitoring Blood glucose meters and test strips Continuous glucose monitoring Non-invasive and emerging technologies

Diabetes Treatment Insulin delivery (including pens and insulin pumps) Open loop continuous glucose monitoring/pumps Closed loop artificial pancreas technology Software & Algorithms

There are a significant number (over 500) of patent assignees. This report provides detailed analysis of:

Overall diabetes patent portfolio (including Priority Year, Patent Totals by Technology, Top Twenty Assignees, IPC and USP Classifications) Diabetes patents by technology subcategory (including Priority Date, Top Twenty Assignees, and Analysis of Sample Patents) Diabetes patents by key company (including Priority Date, Patent Distribution by Technology, and Patent Source Jurisdiction)

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs